As of close of business last night, ReShape Lifesciences Inc.’s stock clocked out at $0.16, down -11.82% from its previous closing price of $0.18. In other words, the price has decreased by -$0.0218 from its previous closing price. On the day, 645957 shares were traded.
Ratios:
To gain a deeper understanding of RSLS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.94 and its Current Ratio is at 1.66. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 25 ’23 when STANKOVICH THOMAS sold 131 shares for $0.27 per share. The transaction valued at 35 led to the insider holds 22,949 shares of the business.
STANKOVICH THOMAS sold 39 shares of RSLS for $36 on Oct 11 ’23. The Chief Financial Officer now owns 23,080 shares after completing the transaction at $0.93 per share. On Sep 01 ’23, another insider, STANKOVICH THOMAS, who serves as the Chief Financial Officer of the company, sold 118 shares for $0.89 each. As a result, the insider received 105 and left with 23,119 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RSLS now has a Market Capitalization of 3.90M and an Enterprise Value of 2.73M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.39 while its Price-to-Book (P/B) ratio in mrq is 0.18. Its current Enterprise Value per Revenue stands at 0.28 whereas that against EBITDA is -0.07.
Stock Price History:
Over the past 52 weeks, RSLS has reached a high of $4.10, while it has fallen to a 52-week low of $0.14. The 50-Day Moving Average of the stock is 0.1830, while the 200-Day Moving Average is calculated to be 0.6189.
Shares Statistics:
It appears that RSLS traded 878.88K shares on average per day over the past three months and 428.37k shares per day over the past ten days. A total of 23.46M shares are outstanding, with a floating share count of 20.84M. Insiders hold about 11.16% of the company’s shares, while institutions hold 1.97% stake in the company. Shares short for RSLS as of Mar 15, 2024 were 428.69k with a Short Ratio of 0.49, compared to 830.82k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.83% and a Short% of Float of 1.83%.
Earnings Estimates
As of right now, 1 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.18 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.18, while EPS last year was -$8.59. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.16 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$3.84 and -$3.84 for the fiscal current year, implying an average EPS of -$3.84. EPS for the following year is -$0.45, with 1 analysts recommending between -$0.45 and -$0.45.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $2.21M. It ranges from a high estimate of $2.21M to a low estimate of $2.21M. As of the current estimate, ReShape Lifesciences Inc.’s year-ago sales were $3.11M, an estimated decrease of -28.90% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $2.1M, a decrease of -8.20% over than the figure of -$28.90% in the same quarter last year. There is a high estimate of $2.1M for the next quarter, whereas the lowest estimate is $2.1M.
A total of 1 analysts have provided revenue estimates for RSLS’s current fiscal year. The highest revenue estimate was $8.9M, while the lowest revenue estimate was $8.9M, resulting in an average revenue estimate of $8.9M. In the same quarter a year ago, actual revenue was $11.24M, down -20.80% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $9.99M in the next fiscal year. The high estimate is $9.99M and the low estimate is $9.99M. The average revenue growth estimate for next year is up 12.20% from the average revenue estimate for this year.
